Predictive model for chemotherapy-associated VTE
| Patient characteristic . | Risk score . |
|---|---|
| Site of cancer | |
| Very high risk (stomach, pancreas) | 2 |
| High risk (lung, lymphoma, gynecologic, bladder, testicular) | 1 |
| Prechemotherapy platelet count 350 × 109/L or more | 1 |
| Hemoglobin level less than 100 g/L or use of red cell growth factors | 1 |
| Prechemotherapy leukocyte count more than 11 × 109/L | 1 |
| BMI 35 kg/m2 or more | 1 |
| Patient characteristic . | Risk score . |
|---|---|
| Site of cancer | |
| Very high risk (stomach, pancreas) | 2 |
| High risk (lung, lymphoma, gynecologic, bladder, testicular) | 1 |
| Prechemotherapy platelet count 350 × 109/L or more | 1 |
| Hemoglobin level less than 100 g/L or use of red cell growth factors | 1 |
| Prechemotherapy leukocyte count more than 11 × 109/L | 1 |
| BMI 35 kg/m2 or more | 1 |